Market news

Detailed price information for Meiragtx Holdings Plc (MGTX-Q) from The Globe and Mail including charting and trades.

MeiraGTx Holdings (NasdaqGS:MGTX) announced two senior leadership appointments, adding executives with extensive global pharmaceutical development and manufacturing experience. The company reported a turnaround in second quarter financial performance, shifting from prior net losses to profitability. Management indicated that these leadership changes and financial results could affect MeiraGTx's pipeline progress and commercialization plans. Consider taking a broader look at related...

MeiraGTx Holdings (MGTX) has an average rating of buy and mean price target of $29.43, according to

MeiraGTx (MGTX) is moving closer to becoming a commercial-stage company, with two potential first-in

MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx (MGTX) reported Q2 net income Thursday of $1.71 per diluted share, swinging from a net loss

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards under the Company’s 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c

The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Stuart Naylor's 4% portfolio reduction follows an 89% one-year stock surge, executed under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025.

MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.